Research programme: Neurological disorders therapeutics - Asceneuron

Drug Profile

Research programme: Neurological disorders therapeutics - Asceneuron

Alternative Names: ASN 120290; ASN-561

Latest Information Update: 12 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck Serono
  • Developer Asceneuron
  • Class Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors; Hexosaminidase C inhibitors; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Progressive supranuclear palsy

Most Recent Events

  • 06 Apr 2017 Asceneuron announces regulatory approval of its CTA to initiate a phase I safety trial of ASN 120290
  • 06 Apr 2017 Asceneuron plans a proof-of-concept phase II trial for Progressive supranuclear palsy (In the elderly) (PO)
  • 06 Oct 2016 Preclinical development is ongoing for Alzheimer's disease in Switzerland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top